TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04563923
Drug: Avdoralimab (IPH5401)
Normalized name: Avdoralimab
DrugBank: Avdoralimab (DB16392)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preparation of avdoralimab and preparation of the syringes are to be performed aseptically by site pharmacy qualified personnel.
Study: NCT02230930
Drug: Hydrocortisone cream 1%
Normalized name: HYDROCORTISONE 10 mg in 1 g TOPICAL CREAM [Hydrocortisone Cream 1% with Aloe Vera]
DrugBank: Hydrocortisone (DB00741)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone cream 1% (1mg/g) will be administered on each nodule one time a day
Study: NCT01842074
Drug: Bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pilot study on the efficacy and safety of bortezomib during desensitization before a living kidney donation
Study: NCT04386122
Drug: FABALOFEN 60
Normalized name: Gablofen
DrugBank: Baclofen (DB00181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dosage: Single dose of one tablet of test product in each period. Administration: 30 minutes before administration, subjects will receive a test meal (high-fat and high-calorie) and finish this meal in 30 minutes or less. Take 1 tablet of test product with 240 mL of water. Lying position or strenuous activities are not allowed within 2 hours post dose
Study: NCT02995187
Drug: Apatinib Mesylate tablet
Normalized name: mesylate
DrugBank: Rivoceranib (DB14765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apatinib 500 mg in tablet once daily
Study: NCT00231075
Drug: Paraplatin
Normalized name: Paraplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00231075
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02926170
Drug: Rivaroxaban
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rivaroxaban will be started at 20 mg/day. Dose will be adjusted according to Cr Clearance. Cr Clearance 30-49 ml/min will receive 15 mg/day.
Study: NCT02926170
Drug: acenocumarol
Normalized name: Acenocumarol
DrugBank: Acenocoumarol (DB01418)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doses will be adjusted according to INR
Study: NCT05701124
Drug: Ranibizumab (0.25 mg/0.025 mL)
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravitreal injection (IVI) was performed under topical anesthesia in standard ophthalmic operating room. 5% povidone-iodine disinfection and topical antibiotic were instilled. Ranibizumab (0.25 mg/0.025 mL) was injected into the vitreous cavity with a 31-gauge needle, aiming the needle directly toward the optic nerve in direction of visual axis 1.0 mm posterior to the corneoscleral junction at the inferotemporal quadrant. The intraocular pressure and central artery perfusion were then checked.
Study: NCT01751919
Drug: Imatinib mesylate tablet 400 mg, 1 Tablet
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00352807
Drug: Brimonidine Purite
DrugBank: Brimonidine (DB00484)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00088985
Drug: vinorelbine ditartrate
DrugBank: Vinorelbine (DB00361)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vinorelbine 25 mg/m2 will be administered intravenously, every 14 days
Study: NCT00381095
Drug: Pregabalin
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Capsule, Flexible-dosing, Double-blind. Treatment duration is 28 days at 100-600 mg/day administered BID+ taper (6 days).
Study: NCT00720434
Drug: PF-00868554
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg BID administered as 5x100 mg tablets for 4 weeks in combination with standard of care; standard of care continued for an additional 44 weeks.
Study: NCT00720434
Drug: PF-00868554
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg BID administered as 3x100 mg tablets for 4 weeks in combination with standard of care; standard of care continued for an additional 44 weeks
Study: NCT00720434
Drug: PF-00868554
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg BID administered as 2x100 mg tablets for 4 weeks in combination with standard of care; standard of care continued for an additional 44 weeks
Study: NCT03068130
Drug: Bardoxolone methyl
Normalized name: Bardoxolone methyl
DrugBank: Bardoxolone methyl (DB05983)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules of Bardoxolone methyl
Study: NCT00275054
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: cycles 1-6: 25 mg/m² i.v., d2-4, q28d
Study: NCT02340780
Drug: Buparlisib
Normalized name: Buparlisib
DrugBank: Buparlisib (DB11666)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00846430
Drug: Peg-Interferon alpha-2b
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: age and weight dependant
Study: NCT00846430
Drug: Temozolomide (temodar)
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: age and weight dependant
Study: NCT00846430
Drug: Vincristine Sulfate (Oncovin)
Normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: age and weight dependant
Study: NCT00099853
Drug: Vildagliptin
Normalized name: Vildagliptin
DrugBank: Vildagliptin (DB04876)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Vildagliptin 50 mg tablets
Study: NCT00099853
Drug: pioglitazone
Normalized name: Pioglitazone
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: pioglitazone 45 mg qd
Study: NCT01356472
Drug: Imipenem/cilastatin
Normalized name: imipenem/cilastatin/relebactam
DrugBank: Cilastatin (DB01597)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: the intervention group was designed for combined linezolid plus imipenem for treating MRSA VAP
Study: NCT01036841
Drug: desmopressin tablet
Normalized name: desmopressin Sublingual Tablet
DrugBank: Desmopressin (DB00035)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administration of desmopressine tablet
Study: NCT01036841
Drug: desmopressin MELT formulation
DrugBank: Desmopressin (DB00035)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administration of desmopressine MELT formulation
Study: NCT00507962
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg/m\^2 Intraarterial On Day 1 Every 4 Weeks
Study: NCT00672412
Drug: GPO-Vir Z30 tablet
Normalized name: tick-borne encephalitis purified antigen
DrugBank: Tick-borne encephalitis vaccine (whole virus, inactivated) (DB16611)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet consisting of ZDV 30 mg/3TC 15 mg/NVP 28 mg taken orally twice daily
Study: NCT00672412
Drug: Lamivudine
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral suspension containing 10 mg 3TC in each mL. Dosage depends on weight.
Study: NCT00672412
Drug: Nevirapine
Normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral solution containing 10 mg NVP in each mL. Dosage depends on weight.
Study: NCT00672412
Drug: Zidovudine
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral solution containing 10 mg ZDV in each mL. Dosage depends on weight.
Study: NCT00002520
Drug: nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03604445
Drug: BI 905677
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for infusion
Study: NCT01267448
Drug: Glipizide XL
Normalized name: GlipiZIDE XL
DrugBank: Glipizide (DB01067)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The control group will receive Glipizide XL (10mg orally) for a total duration of 12 weeks.
Study: NCT01267448
Drug: Saxagliptin + Metformin XR
Normalized name: metformin / saxagliptin Extended Release Oral Tablet
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The intervention group will receive Saxagliptin 5 mg daily for a total duration of 12 weeks.
Study: NCT01267448
Drug: Metformin XR
Normalized name: metformin Extended Release Suspension
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The intervention group will receive Metformin XR 1000 mg daily and will be automatically titrated weekly in 2 weeks to Metformin XR 2000 daily for a total duration of 12 weeks.
Study: NCT01014585
Drug: Milnacipran
Normalized name: MILNACIPRAN
DrugBank: Milnacipran (DB04896)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Milnacipran tablets administered orally twice daily
Study: NCT02580331
Drug: SRP and 1% metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Placement of 1% metformin gel into classII furcation defects after scaling and root planing
Study: NCT02808390
Drug: GED-0507-34-Levo 80 mg
Normalized name: GED-0507-34-Levo
DrugBank: GED-0507-34-Levo (DB16109)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GED-0507-34-Levo 80 mg BID for 8 Weeks
Study: NCT02808390
Drug: GED-0507-34-Levo 160 mg
Normalized name: GED-0507-34-Levo
DrugBank: GED-0507-34-Levo (DB16109)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GED-0507-34-Levo 160 mg BID for 8 Weeks
Study: NCT00330187
Drug: Bupropion SR
Normalized name: Bupropion Hydrochloride 100 MG Oral Tablet, Extended Release, 12 HR [BUPROPION SR]
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupropion SR, with goal dose 300 mg/day, for 6 weeks of active treatment
Study: NCT02249702
Drug: gemcitabine + docetaxel
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02249702
Drug: trabectedin
Normalized name: Trabectedin
DrugBank: Trabectedin (DB05109)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02935309
Drug: Lenvatinib
Normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pre-surgery Lenvatinib, days 1 - 5. Dose Escalation Levels: 1.) 10 mg by mouth (PO) daily (QD); 2.) 14 mg PO QD; 3.) 20 mg PO QD; 4.) 24 PO QD.
Study: NCT00329381
Drug: Xolair
Normalized name: Xolair
DrugBank: Omalizumab (DB00043)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Xolair 150-375 mg SQ every 2 or 4 weeks based on body weight and pre treatment IgE level.
Study: NCT01897077
Drug: Peanut Dissolving Film
DrugBank: Peanut (DB10553)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02923336
Drug: non selective beta blocker
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: the patient is going to receive a device called smart pill before the beginning of treatment with propranolol, after the evaluation with the smart pill device, they are goning to take propranolol (dose of propranolol 80 mg per day) for 4 weeks,finally they will receive another smart pill to evaluate the second gastrointestinal transit time
Study: NCT00106106
Drug: Oral acamprosate
DrugBank: Acamprosate (DB00659)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: For subjects randomized to active treatment, the first 3 acamprosate doses were 1332 mg every 8 hours in an attempt to more rapidly achieve active plasma concentrations, followed by 666 mg acamprosate every 8 hours for the remainder of the study.
Study: NCT03680287
Drug: Within-Subject test of blinded study medication
Normalized name: salicylic acid Medicated Patch [Compound W brand of salicylic acid]
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: On the day after each sleep condition (Uninterrupted Sleep and Sleep Disruption), participants will undergo multiple injections of study medication or placebo. This is a double-blind within-subject Phase II trial. As such, study medications must remain blinded. Participants may receive a medication from one or more of the following categories: prescription stimulants, prescription benzodiazepines, prescription opioids, prescription cannabinoids, over-the-counter medications, or placebo (saline). This study uses a within-subject design, such that participants serve as participants' own control.
Study: NCT04174118
Drug: belcesiran
Normalized name: Belcesiran
DrugBank: Belcesiran (DB18226)
Approvals — FDA: no, EMA: no, PMDA: no
Description: belcesiran will be administered subcutaneously (SC) at dose levels planned.
Study: NCT03811509
Drug: bisphosphonate
Normalized name: Bisphosphonate
DrugBank: [{(5-Chloro-2-Pyridinyl)Amino} Methylene]-1,1-Bisphosphonate (DB03649)
Approvals — FDA: no, EMA: no, PMDA: no
Description: antiresorptives
Study: NCT00997009
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 175 mg/m2 IV day 1, every 21 days
Study: NCT00997009
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: AUC 5 IV day 1 every 21 days
Study: NCT00997009
Drug: cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 400 mg/m2 IV, one week before starting carboplatin and paclitaxel; then 250 mg/m2 IV day 1, weekly
Study: NCT01260454
Drug: Qutenza (8% capsaicin)
Normalized name: Qutenza
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: We will place a Qutenza (8% capsaicin) patch onto an area of normal, anesthetized skin for 60 minutes. Within 28 days, subjects will place a new treprostinil infusion site into the area of Qutenza pre-treated skin.
Study: NCT00400634
Drug: CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN])
Normalized name: Recombinant adeno-associated virus retinal pigment epithelium gene vector AAV2-hRPE65v2
DrugBank: CERE-120 (DB05637)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CERE-120 5.4 x 10\^11 vg
Study: NCT00456898
Drug: desvenlafaxine sustained release (DVS SR)
Normalized name: desvenlafaxine Extended Release Oral Tablet
DrugBank: Venlafaxine (DB00285)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00456898
Drug: Paroxetine
Normalized name: Paroxetine
DrugBank: Paroxetine (DB00715)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03122522
Drug: ipilimumab
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: ipilimumab 3mg/kg
Study: NCT03122522
Drug: nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: nivolumab 1mg/kg
Study: NCT04091763
Drug: Polidocanol Injectable Foam
Normalized name: polidocanol Injectable Foam
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Two distinct periods were considered: intervention and follow-up. During the intervention period patients were observed at 3-week intervals (minimum of 3 weeks and maximum of 9 weeks depending on the number of instrumental treatments performed). The required number of sessions of any of the office-based treatments (maximum of 3 sessions) was determined by clinical and anoscopy response (if after the treatment the participant scored zero points in the Sodergren scale or the anoscopy did not reveal significant hemorrhoidal disease, there was no place for additional instrumental therapy and the patient started the follow-up period.~If there was therapeutic failure at the end of the third session or if there was a significant complication (moderate or severe) the patient's participation in the study ended and he was referred for treatment with other type of office-based procedure or surgery.
Study: NCT03256149
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03513549
Drug: Loxapine 10 MG
Normalized name: loxapine 10 MG
DrugBank: Loxapine (DB00408)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02181023
Drug: Aclidinium Bromide
Normalized name: Aclidinium Bromide
DrugBank: Clidinium (DB00771)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Aclidinium Bromide 322 mcg inhalation powder via Genuair inhaler (Eklira) Product by Almirall, S.A. Ronda General Mitre, 151. ES-08022 Barcelona, Spain
Study: NCT02181023
Drug: Glycopyrronium Bromide
Normalized name: Glycopyrronium bromide
DrugBank: Glycopyrronium (DB00986)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Glycopyrronium Bromide 44 mcg dry powder (capsules) inhaled via Breezehaler inhaler, Seebri - product by Novartis Europharm Limited - Wimblehurst Road, Horsham, West Sussex, RH12 5AB; United Kingdom
Study: NCT01802645
Drug: Cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01802645
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01802645
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01802645
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01802645
Drug: 5-FU
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01802645
Drug: Folinic Acid
Normalized name: Folinic acid
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00709046
Drug: High dose pantoprazole infusion
DrugBank: Pantoprazole (DB00213)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pantoprazole 80mg iv bolus, 8mg/hr infusion for 72hrs
Study: NCT00709046
Drug: Standard dose pantoprazole infusion
DrugBank: Pantoprazole (DB00213)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pantoprazole 40mg iv bolus qd x 3 days
Study: NCT06000514
Drug: Pentavalent antimony (Sbv)
DrugBank: Pentavalent Antimony (DB13047)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cream twice a day in the ulcer(s), during 20 days; and Systemic IV Pentavalent antimony (Sbv) at 20mg/kg/day during 20 days.
Study: NCT02396433
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin will be given on day 1 of each cycle.
Study: NCT02396433
Drug: Eribulin
Normalized name: Eribulin
DrugBank: Eribulin (DB08871)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Eribulin will be given on days 1 and 8 of each cycle.
Study: NCT02396433
Drug: E7449
Normalized name: Talazoparib
DrugBank: Talazoparib (DB11760)
Approvals — FDA: no, EMA: no, PMDA: no
Description: E7449 will be given daily (days 1-21) during each cycle. Patients will continue to receive treatment until progression of disease or discontinuation due to unacceptable side effects.
Study: NCT01375764
Drug: Ezetimibe
Normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered orally once a day
Study: NCT00946309
Drug: High Sulforaphane Extract (Broccoli Sprout Extract)
Normalized name: high-density polyethylene
DrugBank: Sulforaphane (DB12422)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 umol sulforaphane, every other day for 5 weeks
Study: NCT00946309
Drug: Microcrystalline Cellulose NF (placebo)
Normalized name: Microcrystalline Cellulose
DrugBank: Microcrystalline cellulose (DB14158)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg every other day for 6 weeks
Study: NCT03390738
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous nivolumab 240mg every 2 weeks until radiologically-documented disease progression, unacceptable toxicity as judged by investigators or patient withdrawal
Study: NCT02049047
Drug: Everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Everolimus will be orally administered at the dosage of 10 mg once daily. Each cycle will be considered as 21 days of treatment. Tumor assessment will be done every two cycles.Treatment should be administered until documented disease progression, unacceptable toxicity, or patient refusal.
Study: NCT04909684
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The approved doses of 400 mg every 6 weeks (Q6W) and 200 mg every 3 weeks (Q3W) will be decreased to a 300 mg Q6W dose. The approved dose of 150 mg Q3W will be decreased to a 100 mg Q3W dose.
Study: NCT03824912
Drug: Ketoconazole Cream 2%
DrugBank: Ketoconazole (DB01026)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will be instructed to apply sufficient study product to cover affected and immediate surrounding areas once daily for 42 ± 4 days. Each patient is expected to receive 42 ± 4 doses.
Study: NCT03824912
Drug: Ketoconazole Cream 2% (G&W Laboratories Inc.)
DrugBank: Ketoconazole (DB01026)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will be instructed to apply sufficient study product to cover affected and immediate surrounding areas once daily for 42 ± 4 days. Each patient is expected to receive 42 ± 4 doses.
Study: NCT03174236
Drug: Ceftriaxone
Normalized name: Ceftriaxone
DrugBank: Ceftriaxone (DB01212)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ceftriaxone a third-generation cephalosporin. Ceftriaxone is active against a broad spectrum of Gram positive and Gram negative bacteria.
Study: NCT03174236
Drug: Benzyl penicillin
Normalized name: Benzyl Alcohol
DrugBank: Benzylpenicillin (DB01053)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The currently recommended first-line antibiotics for the treatment of severe acute malnutrition are gentamicin plus ampicillin or penicillin.
Study: NCT04055233
Drug: Polihexanide; Serasept
DrugBank: Polihexanide (DB12277)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental arm: irrigation of subcutaneous tissue after fascia closure with polihexanide (ten minutes).~A single dose of perioperative antibiotics (cefuroxim alone or cefuroxim and metrodidazole in bowel surgeries) was given 30 minutes before skin incision.~Hair removal was done with electronic clippers and preoperative skin antisepsis was performed with propanol and povidone-iodine.~Before closure of fascia, instruments and gloves were changed. No subcutaneous suture was used. Skin was closed either with skin staples, continuous intracutaneous suture or interrupted suture.~All surgeries were done according to the Standard Operating Procedures of the Department for General, Visceral and Vascular Surgery, Charité Campus Benjamin Franklin.
Study: NCT03174236
Drug: Metronidazole
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The WHO guidelines recommend that Metronidazole may be given in addition to broad-spectrum antibiotics, however, the efficacy of this treatment has not been established in clinical trials.
Study: NCT02199899
Drug: BIIF 1149 BS - single rising doses
Normalized name: Rise Prot-72
DrugBank: RP-72 (DB17156)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01751867
Drug: Decitabine at 15 mg/m2
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Decitabine will be given at a dose of 15 mg/m2 as a continuous intravenous infusion within a 3-hour intravenous infusion, repeated every 8 hours for 3 consecutive days.The total dose per day is 45 mg/m2; The total dose per course is 135 mg/m2. Cycles will be repeated every 6 weeks.